PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för linagliptin. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

74 hits

Bibliografisk träff 2010-12-01

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

Forst T, Uhlig-Laske B, Ring A, Graefe-Mody U, Friedrich C, Herbach K, Woerle HJ, Dugi KA.

Diabet Med · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/j.1464-5491.2010.03131.x

Bibliografisk träff 2010-11-12

Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects.

Graefe-Mody U, Rose P, Ring A, Ring A, Zander K, Iovino M, Woerle HJ.

Drug Metab Pharmacokinet · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.2133/dmpk.dmpk-10-rg-091

Bibliografisk träff 2010-10-01

Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers.

Graefe-Mody EU, Jungnik A, Ring A, Woerle HJ, Dugi KA.

Int J Clin Pharmacol Ther · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.5414/cpp48652

Bibliografisk träff 2010-06-10

The dipeptidyl peptidase-4 inhibitor linagliptin exhibits time- and dose-dependent localization in kidney, liver, and intestine after intravenous dosing: results from high resolution autoradiography in rats.

Greischel A, Binder R, Baierl J.

Drug Metab Dispos · research support, non-u.s. gov't; journal article · DOI 10.1124/dmd.110.034199

Bibliografisk träff 2010-06-01

Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin.

Graefe-Mody U, Huettner S, Stähle H, Ring A, Dugi KA.

Int J Clin Pharmacol Ther · controlled clinical trial; research support, non-u.s. gov't; journal article · DOI 10.5414/cpp48367

Bibliografisk träff 2010-06-01

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.

Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, Graefe-Mody EU, Woerle HJ, Dugi KA.

Clin Ther · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1016/j.clinthera.2010.06.004

Bibliografisk träff 2010-02-16

Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients.

Retlich S, Duval V, Graefe-Mody U, Jaehde U, Staab A.

J Clin Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1177/0091270009356444

Bibliografisk träff 2010-01-19

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans.

Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K.

Drug Metab Dispos · randomized controlled trial; journal article · DOI 10.1124/dmd.109.031476

Bibliografisk träff 2010-01-01

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.

Deacon CF, Holst JJ.

Expert Opin Investig Drugs · research support, non-u.s. gov't; review; journal article · DOI 10.1517/13543780903463862

Bibliografisk träff 2009-11-01

Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats.

Retlich S, Withopf B, Greischel A, Staab A, Jaehde U, Fuchs H.

Biopharm Drug Dispos · journal article · DOI 10.1002/bdd.676

Bibliografisk träff 2009-10-01

Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.

Tiwari A.

Curr Opin Investig Drugs · review; journal article

Bibliografisk träff 2009-09-05

Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo.

Horie Y, Hayashi N, Dugi K, Takeuchi M.

Trials · clinical trial, phase iii; clinical trial, phase ii; comparative study; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1186/1745-6215-10-82

Bibliografisk träff 2009-08-01

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.

Graefe-Mody EU, Padula S, Ring A, Ring A, Withopf B, Dugi KA.

Curr Med Res Opin · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1185/03007990903094361

Bibliografisk träff 2009-05-19

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommeshauser D, Dugi KA.

Diabetes Obes Metab · multicenter study; randomized controlled trial; journal article · DOI 10.1111/j.1463-1326.2009.01046.x